【新唐人2013年12月25日訊】中國大陸傳出新生兒接種B肝疫苗後死亡，目前已知有8名嬰兒在注射問題疫苗之後，發生異常反應而死亡。深圳市疾病預防控制中心23號才通報，全面停用某公司的乙肝疫苗。外界質疑，為甚麼要等到悲劇發生後，有關部門才對「疑似問題疫苗」全面叫停？而且僅僅只是通報「一停了之」，完全忽視民眾對「問題疫苗」的知情權。民眾質疑，難道這其中還隱藏甚麼不為人知的貓膩？
連日來，湖南、四川、廣東多地發生嬰兒接種乙肝疫苗後死亡事件，引發公眾對疫苗安全性的擔憂。
廣東省疾控中心證實，深圳一名新生嬰兒12月17號接種乙肝疫苗68分鐘後死亡。11月以來，廣東先後發生了4例疑似接種乙肝疫苗後死亡的病歷。此外，湖南、四川等地也先後出現新生兒在接種乙肝疫苗後死亡案例。
12月21號，四川眉山居民高兵之子在眉山「中鐵醫院」出生，隔天接種乙肝疫苗，10多個小時後死亡。高兵及家屬懷疑，孩子死亡疑似與接種乙肝疫苗有關。
據了解，這些問題疫苗是由深圳「康泰公司」生產，這家公司所製造的乙肝疫苗，市場占有率高達50%以上，然而相對的應變措施卻如此遲緩。
23號下午，深圳市藥品監督管理局通報，深 圳「康泰生物製品股份有限公司」生産的重組乙肝疫苗，在庫成品已全部暫停銷售及發運工作，在有效期內的重組乙肝疫苗各規格已銷售186批次，合計35,891,194支。但通告並沒有說明已銷售疫苗的使用和流向情況。
民間公益團體「食品藥品安全宣導聯盟」成員姬來松律師表示，這件事情發生在中國，一點都不覺得吃驚。
河南律師姬來松：「出現這個事情，讓我們想起幾年前的三鹿奶粉事件，我覺得這個事情的發生和當初的三鹿奶粉其實是一樣的，還是監管不力，食品安全和藥品安全的機構都是不作為，或者是亂作為，這是導致這次事件發生的最根本的原因。」
山西疫苗受害家長易文龍表示，衛生部門打擊力度不夠，所以造成越來越多有關疫苗品質異常反應的問題。
山西疫苗受害家長易文龍：「我們是普通老百姓，我們也沒有能力去調查到底有多少例，但據我知道我們全村有幾百例吧，這個疫苗造假，不單純的是報導的假疫苗，這個疫苗發生異常反應，這就是廠家賠錢，這就涉及到官商勾結的問題，衛生部門說，他不可能因為這些少數的家長而影響大眾的接受 疫苗，他不敢承認的意思，怕引起接受疫苗的恐慌。」
按照規定，疫苗產品上市銷售前，必須通過「中國食品藥品檢定研究院」的檢驗，並獲得生物製品批簽發合格證。根據媒體報導，深圳「康泰生物」出事的重組乙肝疫苗，都按規定獲得了合格證。但儘管通過檢驗，還是出了問題。
據了解，「康泰生物」並不是第一次出事。2010年，廣東揭陽市惠來縣46名學生接種「康泰生物」公司生産的乙肝疫苗後，曾出現頭暈、噁心、全身無力等症狀而住院治療，但當時的廣東省衛生部門表示，那批疫苗沒有問題。最後也是不了了之。
姬來松：「我認為最主要的還是體制問題，一個不受監督的體制、不受監督的權力，他肯定就是為所慾為，他根本不把人民的生命健康放在眼裡，只要他們維護他的體制、維護他的利益，那這些東西他就可以忽略。」
姬來松表示，對於注射問題疫苗造成多起嬰幼兒死亡事件，衛生部門不能隨便找一個替罪羊來頂替，把深層次的問題給掩蓋，如果不公布問題疫苗的流向和原因，那麼這絕對不是第一例，也不是最後一例，中國民眾的生命安全堪慮。
採訪/常春 編輯/黃億美 後製/郭敬
Chinese concerned over unclear information on problem hepatitis B vaccines
Another newborn baby recently died from a hepatitis B vaccine
in mainland China, while seven babies in three provinces also
had abnormal reactions and died after getting the same vaccine.
On Dec. 23, the Shenzhen Center for Disease Control and
Prevention issued a notice banning the vaccine.
Many are questioning why the health department
did not recall the vaccines until accidents happened.
The notice to ban the vaccine did not explain
where the questioned vaccines have gone to.
People’s rights to know have been
completely ignored by the authorities.
People questioned whether there is something being hidden.
In the past few days, babies in Hunan, Sichuan and Guangdong
provinces have been dying from hepatitis B vaccinations,
triggering public concerns about vaccine safety.
The Guangdong Center for Disease Control confirmed that a
newborn baby in Shenzhen died an hour after receiving the
hepatitis B vaccine on Dec. 17.
Since November, four babies in Guangdong province are
suspected to have died from the hepatitis B vaccination.
Newborn deaths after hepatitis B vaccination
has also appeared in Hunan, Sichuan and other regions.
On Dec. 21, the son of Gao Bing, a Meishan City resident in
Sichuan province, was born in Meishan Railway Hospital
and died 10 hours after hepatitis B vaccination.
Gao Bing and his family suspect the baby’s death
was related to the hepatitis B vaccine.
The vaccine is reportedly produced
by the Shenzhen-based company Biokangtai.
Their hepatitis B vaccine has an over 50% market share, but
relatively slow contingency measures.
On Dec. 23, the Shenzhen Drug Administration reported that
the recombinant hepatitis B vaccines produced by Biokangtai
have been suspended from selling and shipping.
Up until then, nearly 200 batches of the vaccine
have been sold, totaling nearly 36 million doses.
But the notice did not specify how the vaccines have been used
and where the vaccines were sold to.
Non-profit group “food and drug safety advocacy coalition"
lawyer Ji Laisong says such things are not surprising in China.
Ji Laisong, Henan lawyer: “The hepatitis B vaccine incident
reminds me of the Sanlu milk powder scandal a few years ago.
I believe this case and Sanlu milk powder case
are all due to lack of supervision.
The primary reason is because food safety and
pharmaceutical safety agencies do not act, or act disorderly."
Shanxi resident Yi Wenlong, who’s child was a victim, says
the series of abnormal reactions from the vaccine results from
the health department’s inadequate crackdown on such issues.
Yi Wenlong, Shanxi resident and parent of vaccine victim:
“We ordinary people do not have the ability to investigate.
As I know there are hundreds of victim’s cases in our village.
The counterfeit vaccine wasn’t simply reported as such,
but as an abnormal reaction from the vaccine.
Since the manufacturers will lose money,
it relates to the issue of collusion.
The health department will not impact majority infants’
vaccination because of the minority parents.
They dare not admit it for fear of people refusing the vaccine."
According to regulations, before being released, vaccine
products must pass “Chinese Academy of Food and Drug
Adiministration" tests and get certification to release batches
of biological products.
Media reports say the recombinant hepatitis B vaccine
from Biokangtai obtained the certificate and
passed the inspection, yet still had problems.
This was not the first accident for Biokangtai.
In 2010, after 46 students in Guangdong’s Huilai County
were hospitalized due to dizziness, nausea, and weakness after
receiving Biokangtai’s hepatitis B vaccine.
But the Guangdong Provincial Health Department said
the batches of the vaccine had no problem
and left the issue unresolved.
Ji Laisong: “I think the main problem is still the system.
Under an unmonitored system, they certainly do as they please
and ignore people’s wellbeing with unsupervised power, as
long as they maintain that system
they can safeguard their interests."
Ji Laisong says the health department can’t just find a scapegoat
to hide deep-rooted problems for so many infant deaths caused
by the vaccine injection.
This is definitely not the first case, nor the last if information
isn’t released on how the vaccines were used and the cause of
the problem. This is a big safety concern for people in China.
Interview/ChangChun Edit/HuangYimei Post-Production/GuoJing
